Kymera Therapeutics
KYMR
110 hedge funds and large institutions have $1.29B invested in Kymera Therapeutics in 2021 Q2 according to their latest regulatory filings, with 37 funds opening new positions, 45 increasing their positions, 16 reducing their positions, and 24 closing their positions.
15,471% more call options, than puts
Call options by funds: $7.47M | Put options by funds: $48K
181% more repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 16
54% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 24
45% more capital invested
Capital invested by funds: $887M → $1.29B (+$401M)
13% more funds holding
Funds holding: 97 → 110 (+13)
8.02% more ownership
Funds ownership: 50.95% → 58.97% (+8%)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$40.6M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$39.6M |
| 3 |
EC
EcoR1 Capital
San Francisco,
California
|
+$18.2M |
| 4 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$17.8M |
| 5 |
State Street
Boston,
Massachusetts
|
+$17.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DIC
Deer IX & Co
Larchmont,
New York
|
-$18.5M |
| 2 |
Janus Henderson Group
London,
|
-$15.5M |
| 3 |
Morgan Stanley
New York
|
-$12.5M |
| 4 |
LGM
Logos Global Management
San Francisco,
California
|
-$10.1M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$7.38M |
KYMR Hedge Fund Activity: Q2 2021 in Review
110 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in Kymera Therapeutics (KYMR) for Q2 2021, worth a combined $1.29B — up 45% from $887M a quarter earlier.
Buyers outnumbered sellers: 37 funds opened new KYMR positions and 24 closed out — a net gain of 13 holders — while 45 added to existing stakes and 16 trimmed.
The largest buyer was BlackRock, adding an estimated $40.6M. The largest seller was Deer IX & Co, cutting an estimated $18.5M.
- 110 institutional investors held Kymera Therapeutics (KYMR) as of Q2 2021, up from 97 in Q1 2021.
- Funds reported $1.29B of Kymera Therapeutics stock for Q2 2021, up 45% quarter-over-quarter.
- 37 funds opened new Kymera Therapeutics positions in Q2 2021 and 24 closed out, a net change of +13 holders.
- The largest Kymera Therapeutics buyer in Q2 2021 was BlackRock, an estimated $40.6M added.
- The largest Kymera Therapeutics seller in Q2 2021 was Deer IX & Co, an estimated $18.5M sold.
Based on aggregated 13F filings for Q2 2021.